Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 63.4312
- Book/Share 11.5372
- PB 26.3115
- Debt/Equity 9.2446
- CurrentRatio 1.1704
- ROIC 0.0953
- MktCap 163226033360.0
- FreeCF/Share 20.2881
- PFCF 14.9543
- PE 27.5266
- Debt/Assets 0.6421
- DivYield 0.0305
- ROE 0.9294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
Downgrade | AMGN | Truist | Buy | Hold | $320 | $333 | Oct. 14, 2024 |
Initiation | AMGN | Cantor Fitzgerald | -- | Overweight | -- | $405 | Sept. 27, 2024 |
News
10 Undervalued Dividend Growth Stocks: February 2025
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.
Read More
These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
Published: February 25, 2025 by: The Motley Fool
Sentiment: Positive
How is the Dow Jones Industrial Average (^DJI 0.08%) performing this year? It might depend on whether you view the proverbial glass of water as half-empty or half-full.
Read More
Amgen plans $200 million investment in India site, CEO says
Published: February 24, 2025 by: Reuters
Sentiment: Positive
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert A. Bradway said at the inauguration of the site.
Read More
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen, Inc. (NASDAQ:AMGN ) Citi's 2025 Virtual Oncology Leadership Summit Conference Call February 19, 2025 3:00 PM ET Company Participants Jean-Charles Soria - Senior Vice President of R&D Justin Claeys - Vice President of Investor Relations Conference Call Participants Geoffrey Meacham - Citigroup Geoffrey Meacham Hello, good afternoon. My name is Geoff Meacham.
Read More
AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
THOUSAND OAKS, Calif. , Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m.
Read More
Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen, Inc. (NASDAQ:AMGN ) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Company Participants Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - Head of Investor Relations Casey Capparelli - Investor Relations Conference Call Participants Jay Olson - Oppenheimer & Co. Jay Olson Hello, everyone. I'm Jay Olson, one of the biotech analysts at Oppenheimer, and it's a pleasure to welcome you to Oppenheimer's 35th Annual Healthcare Conference.
Read More
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
3 Fabulous Dividend Stocks to Buy in February
Published: February 09, 2025 by: The Motley Fool
Sentiment: Positive
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000